Publicaciones en colaboración con investigadores/as de Ohio State University (14)

2023

  1. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

    British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. COVID-19, asthma, and biological therapies: What we need to know

    World Allergy Organization Journal, Vol. 13, Núm. 5

2019

  1. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

    European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973

  2. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1

    Leukemia, Vol. 33, Núm. 8, pp. 1910-1922

2017

  1. Myeloma in Elderly Patients: When Less Is More and More Is More

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, Vol. 37, pp. 575-585

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

    Leukemia, Vol. 30, Núm. 11, pp. 2179-2186

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. Identification of six new susceptibility loci for invasive epithelial ovarian cancer

    Nature Genetics, Vol. 47, Núm. 2, pp. 164-171

2014

  1. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

    British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477

2012

  1. Guidelines for the use and interpretation of assays for monitoring autophagy

    Autophagy, Vol. 8, Núm. 4, pp. 445-544

2010

  1. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

    Blood, Vol. 116, Núm. 25, pp. 5650-5659

2004

  1. Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, Núm. 16, pp. 6226-6230